Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human islet amyloid polypeptide (hIAPP) oligomers are soluble, aggregated forms of the 37-residue peptide hormone hIAPP/amylin. These oligomers are implicated in the pathogenesis of type 2 diabetes mellitus (T2D) due to their toxicity to pancreatic β-cells. They disrupt cell membranes, induce apoptosis, and interfere with insulin secretion. The core region responsible for aggregation lies within residues 20–29. Metal ions, particularly Cu(II), can influence the oligomerization pathway and increase toxicity.
Disruption of cell membranes, leading to increased permeability and/or direct lysis, particularly in pancreatic β-cells, ultimately triggering apoptosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Islet Amyloid Polypeptide Oligomer.